Natural history of dR modified by anti-VEGF treatment
Analysis of patients with diabetic macular oedema (DME) who participated in the RISE and RIDE phase III trials demonstrates that ranibizumab reduces diabetic retinopathy severity in many patients, and can slow the clinical progression of the disease, according to a presentation at the 13th EURETINA Congress.
“These data underscore the need for early screening and appropriate intervention in DME patients, who without treatment are at high risk of developing proliferative diabetic retinopathy,” said Patricio G Schlottmann MD.
Latest Articles
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Nutrition and the Eye: A Recipe for Success
A look at the evidence for tasty ways of lowering risks and improving ocular health.
New Award to Encourage Research into Sustainable Practices
Sharing a Vision for the Future
ESCRS leaders update Trieste conference on ESCRS initiatives.
Extending Depth of Satisfaction
The ESCRS Eye Journal Club discuss a new study reviewing the causes and management of dissatisfaction after implantation of an EDOF IOL.
Conventional Versus Laser-Assisted Cataract Surgery
Evidence favours conventional technique in most cases.
AI Scribing and Telephone Management
Automating note-taking and call centres could boost practice efficiency.